ZVS106e subretinal injection for Stargardt disease from two ABCA4 mutations

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This early-phase 1 interventional study gives a single monocular subretinal injection of ZVS106e to patients with hereditary retinal degeneration caused by biallelic ABCA4 mutations. The primary aim is to collect preliminary safety data after the injection, while secondary and exploratory endpoints will track changes in retinal structure and visual function. Efficacy signals will be explored both in the injected eye and by comparing the non-injected eye to baseline measurements. Participants will be recruited at major ophthalmic centers in China and will undergo scheduled imaging and functional testing during follow-up.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥8 years old;
2. Patients diagnosed with hereditary retinal degeneration caused by ABCA4 biallelic mutations through genetic testing, and without other ophthalmic genetic diseases;
3. The target eye must meet the following requirements: the best corrected visual acuity is 0.5 to 2.0 LogMAR (including 0.5 and 2.0 LogMAR, equivalent to the decimal visual acuity index up to 0.3);
4. The subject and his or her spouse agree to take effective contraceptive measures during the trial period and for at least one year after administration.
5. Voluntarily participate in clinical trials and sign informed consent forms, and be able to complete all trial processes as required by the protocol.

Exclusion Criteria:

1. The researchers determined that the target eye currently has or has previously had other macular lesions such as retinal schisis or epiretinal membrane. Or have other eye diseases that may hinder the surgery or interfere with the interpretation of the study endpoint;
2. Having received drug treatment that may affect the observation of the trial within the three months prior to screening;
3. The target eye has undergone the following intraocular surgeries: retinal repositioning and vitrectomy;
4. There are known eye/visual diseases, disorders or lesions that cause or are related to vision loss, or whose related treatments or therapies are known to cause or are related to vision loss;
5. Having suffered from a viral infectious disease that may affect the efficacy and safety evaluation of the investigational drug or having received an antiviral vaccine within one month prior to enrollment;
6. Systemic medications that are currently in use or may be required to cause eye toxicity, such as psoralen, risselinic acid or tamoxifen, etc.
7. Known to be allergic to the drugs planned to be used in the study;
8. Suffering from poorly drug-controlled hypertension: systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg;
9. The following laboratory test abnormalities have clinical significance:

   Liver function: Chronic liver disease, elevation of ALT or AST \>2 times the upper limit of the normal value; Those with abnormal coagulation function (prothrombin time ≥ 3 seconds above the upper limit of the normal value, activated partial thromboplastin time ≥ 10 seconds above the upper limit of the normal value); Serum virological examination: Positive for active hepatitis B, hepatitis C virus antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab), or syphilis antibody;
10. There is any past or current medical history that may affect the safety of the trial or the in vivo process of the drug, especially a history of diseases such as cardiovascular, liver, kidney, endocrine, digestive tract, lung, nervous, hematological, tumor, immune or metabolic disorders that the investigators consider to have clinical significance;
11. Those who have participated in any clinical trials of drugs or medical devices within the three months prior to screening;
12. Pregnant or lactating women; According to the researcher's judgment, those who are deemed unsuitable to participate in this clinical trial for other reasons

Where it's running

• Peking University Third Hospital
  Beijing, Beijing Municipality, China Recruiting
• Zhongshan Ophthalmic Center, Sun Yat-sen University
  Guangzhou, Guangdong, China Not yet recruiting

Study contacts

• Principal investigator: lin Lv, M.D — Pi
• Study coordinator: dayou Ding
• Email: dingdayou@chinagene.cc
• Phone: 010-82266699

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Observing the progression of Stargardt Disease Type 1

  This study is tracking how Stargardt Disease Type 1 progresses in about 75 people to better understand the condition and help improve future treatments.

  Recruiting at 20 sites Splice Bio · San Diego, California and 19 other locations · NCT06435000

• See how streetscape exposure might influence kids’ vision and perceptions

  This study tests whether a virtual street environment affects how children with and without myopia perceive visual and psychological cues.

  Recruiting Zhongshan Ophthalmic Center, Sun Yat-sen University · Guangzhou, Guangdong · NCT07761949

• Mapping how the human retinal and visual brain tissues develop

  This study tests how retinal nerve cells and related brain regions grow and connect in human embryos, using donated embryonic tissues from terminated pregnancies.

  Recruiting Zhongshan Ophthalmic Center, Sun Yat-sen University · Guangzhou, Guangdong · NCT07688538

• Smartphone-based AI eye disease screening for anterior segment conditions

  A smartphone-powered AI system tests whether it can identify 16 eye conditions from images captured on a phone, without needing internet access, in adults.

  Recruiting Zhongshan Ophthalmic Center, Sun Yat-sen University · Guangzhou, Guangdong · NCT07634913

• Choroid and retina imaging in angle‑closure versus open‑angle glaucoma using OCT and OCTA

  This project will use OCT and OCTA eye scans to see if choroidal and retinal features differ between people with primary angle‑closure disease, primary open‑angle glaucoma, and healthy volunteers.

  Recruiting Zhongshan Ophthalmic Center, Sun Yat-sen University · Guangzhou, Guangdong · NCT07580014

• Impact of Phaco Tip Location on Early Postoperative Outcomes in Cataract Surgery

  This observational study tests whether the position of the phacoemulsification tip during cataract surgery affects early changes in the cornea and vision in people with age-related cataracts.

  Recruiting Zhongshan Ophthalmic Center, Sun Yat-sen University · Guangzhou, Guangdong · NCT07550907

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.